Karapet Davtyan, Ivan Chugunov, Arpi Topchyan, Yury Mareev, Natalia Mironova, Elena Rimskaya, Sergey Golitsyn, Evgeny Mikhaylov, Dmitry Lebedev, Marianna Vander, Elena Lyasnikova, Maria Sitnikova, Khatuna Minjia, Svetlana Glembo, Oleg Sukhorukov
OBJECTIVES: Our study aimed to assess the safety and efficacy of cardiac contractility modulation (CCM) therapy in patients with heart failure with reduced ejection fraction (HFrEF) depending on HF etiology. METHODS: We enrolled 166 patients with optimal medical therapy-resistant HFrEF (median age 59 years, 83.7% males, median NYHA class - 2, median left ventricular ejection fraction (LVEF) - 29.0%) who underwent CCM therapy device implantation from 2013 to 2019 in four medical centers in Russia...
May 29, 2024: BMC Cardiovascular Disorders